Biomarkers in chronic obstructive pulmonary disease: confusing or useful?

Stockley, Robert A.

doi:10.2147/copd.s42362

Cited by 33 publications

(19 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the role of biomarkers in respiratory diseases constitutes the focus of much research [3][4][5] . However, there is little data concerning their usefulness among patients who suffer from occupational respiratory diseases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of biomarkers in serum and induced sputum of patients with occupational asthma and chronic obstructive pulmonary disease

Kleniewska

Walusiak‐Skorupa

Piotrowski

et al. 2016

Journal of Occupational Health

View full text Add to dashboard Cite

Objectives: Occupational asthma and chronic obstructive pulmonary disease (COPD) are associated with the airway inflammatory process. The aim of this study was to compare the sputum and serum markers of inflammation in patients with occupational asthma and COPD. Methods: The study group included 20 patients with stable COPD, 24 patients with asthma, and 22 healthy subjects. Interleukin (IL)-6, IL-1β, tumor necrosis factor (TNF)-α, matrix metalloproteinase (MMP)-9 levels in serum and induced sputum as well as fibrinogen and CRP in serum were determined in all the subjects. Results: Higher concentrations of IL-1β, IL-6, TNF-α, and MMP-9 in induced sputum and an increased concentration of acute-phase proteins in serum were observed in COPD patients compared with healthy subjects. Higher concentrations of IL-1β and MMP-9 in induced sputum and a higher concentration of C-reactive protein (CRP) were detected in COPD patients than in asthmatic subjects. Never smokers with COPD had significantly higher levels of IL-1β and MMP-9 in induced sputum than never smoker controls. There was no significant difference between the serum and sputum levels of cytokines and MMP-9 of never smokers and smokers with COPD. Conclusions: Higher concentrations of IL-1β and MMP-9 in induced sputum and a higher concentration of CRP in serum allow distinguishing between biomarker profiles of COPD patients and asthmatic patients. Occupational exposure induces a systemic proinflammatory state with increased levels of acute-phase proteins in stable COPD patients. MMP-9 and IL-1β concentrations are increased in induced sputum of never smokers with COPD, which is associated with occupational exposure.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In general, asthma and COPD are associated with an inflammatory process [1][2][3] . Matrix metalloproteinase-9 (MMP-9), interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α and acute-phase protein such as fibrinogen, and C-reactive protein ( CRP ) may all be involved in their pathogenesis 1,4) .…”

Section: Introductionmentioning

confidence: 99%

Comparison of biomarkers in serum and induced sputum of patients with occupational asthma and chronic obstructive pulmonary disease

Kleniewska

Walusiak‐Skorupa

Piotrowski

et al. 2016

Journal of Occupational Health

View full text Add to dashboard Cite

show abstract

“…At the same time, there is an interest to increase their widespread applicability. 59,60 Evaluation of different subgroups of COPD (phenotypes) will be significantly more nuanced and easier with closer monitoring of specific markers. The use of biomarkers in COPD characterization will find its place in the guideline recommendations for disease diagnosis, prevention and treatment.…”

Section: Markers In Studymentioning

confidence: 99%

Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease

Comes

Ianoși

Jimborean

2016

Journal of Interdisciplinary Medicine

View full text Add to dashboard Cite

Chronic obstructive lung disease (COPD) is a severe progressive disease associated with high morbidity and mortality. Early diagnosis and correct treatment improve the symptoms, quality of life and survival in COPD. Exacerbations of the disease are acute events that cause worsening of COPD symptoms (dyspnea, cough and/or sputum) and may require modification of stable COPD therapy. COPD exacerbations add inflammation, damage the quality of life, deteriorate the lung function, increase mortality and associate high socio-economic costs. Accurate early prediction of exacerbation and mortality risk facilitates patient selection upon risk, in order to provide appropriately targeted early treatment. The risk of having frequent exacerbations is clearly demonstrated by recognized studies in patients with specific criteria: previous exacerbation in the last year, decrease in FEV1s, increase in the score of St. George Questionnaire (life quality decline), high levels of several inflammatory biomarkers, such as neutrophils, C-reactive protein (CRP), fibrinogen, pro-calcitonin, eosinophils, IL-6, IL-8, chemokine ligand 18 (CCL-18/PARC), surfactant protein D (SP-D). Simultaneously elevated levels of CRP, fibrinogen and leukocyte count in COPD patients were associated with an increased risk for exacerbations. At the same time, elevated levels of the three biomarkers are associated with an increased risk of major comorbidities in COPD. Biomarker detection may be an additional tool for assessment and management of COPD comorbidities. Detection of pathologic levels of inflammatory biomarkers improves the ability to predict the risk mortality in COPD alongside with BODE index (BMI, obstruction in lung function, dyspnea scale, 6-minute walk test) and may provide a targeted treatment.

show abstract

“…All the proteins on this list have been shown or suggested to be linked to the pathogenesis of the disease, an important criterium in the selection of useful biomarkers in COPD [2] . Indeed this list reflects the complexity of the underlying pathogenesis of COPD, involving inflammation, oxidative stress (e.g., due to smoking), the protease/anti-protease imbalance, environmental factors (such as exposure to pollutants or internal cooking), and genetic predispositions [5,59] . Accumulating evidence indicates that chronic inflammatory and immune responses play key roles in the development and progression of COPD [60,61] .…”

Section: Copd Protein Biomarkersmentioning

confidence: 99%

“…Examples of such phenotypes are chronic bronchitis, emphysema, chronic mucus hypersecretion and small airways thickening. Besides encompassing pulmonary components, this term also covers additional features such as exacerbations and comorbidities, since COPD is recognized as a complex and multicomponent syndrome with both pulmonary and extrapulmonary manifestations [1,[3][4][5] . The forced expiratory volume in 1 second (FEV 1 ) is the current "gold standard" marker of disease progression, response to therapy, and prediction of mortality [6] .…”

Section: Introductionmentioning

confidence: 99%

Prioritization of COPD protein biomarkers, based on a systematic study of the literature

Camacho¹,

Klont²,

Horvatovich³

et al. 2016

Adv Precis Med

View full text Add to dashboard Cite

Chronic Obstructive Pulmonary Disease (COPD) is a chronic lung disease mostly due to smoking and until now diagnosed by spirometry (post bronchodilator FEV 1 /FVC <70%). However, in spite of the usefulness of FEV 1 as diagnostic and prognostic tool, it has proven to be a weak indicator of future exacerbations, unable to predict lung function decline within COPD patients, as well as unable to identify the smokers "susceptible" to developing COPD at an early stage. Thus, there is an urgent need for biomarkers that address these questions and support clinical decision making in the diagnosis and treatment of (early) COPD. In this respect, considerable efforts have been devoted to identifying protein biomarkers that enable a better understanding of this complex disease and leading to better diagnostic and prognostic tools. However, in spite of the wide range of candidates that have been suggested as potentially useful COPD biomarkers, most remained at the level of the initial discovery, and only fibrinogen has been approved by the Food and Drug Administration (FDA) as predictor for all-cause mortality and COPD exacerbations. There is thus a need for future investigations of these biomarkers in large-scale and well characterized studies in order to prove their usefulness as surrogate endpoints. Based on this, the aim of the present review is to advance COPD biomarker development by providing a comprehensive overview of protein biomarker candidates which have been evaluated in clinical studies and prioritize them according to their potential of becoming valid, clinically useful COPD biomarkers.

show abstract

Biomarkers in chronic obstructive pulmonary disease: confusing or useful?

Cited by 33 publications

References 115 publications

Comparison of biomarkers in serum and induced sputum of patients with occupational asthma and chronic obstructive pulmonary disease

Comparison of biomarkers in serum and induced sputum of patients with occupational asthma and chronic obstructive pulmonary disease

Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease

Prioritization of COPD protein biomarkers, based on a systematic study of the literature

Contact Info

Product

Resources

About